0000950103-16-014334.txt : 20160624 0000950103-16-014334.hdr.sgml : 20160624 20160624144404 ACCESSION NUMBER: 0000950103-16-014334 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160624 FILED AS OF DATE: 20160624 DATE AS OF CHANGE: 20160624 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Anacor Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001411158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 251854385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1020 E. MEADOW CIRCLE CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: 650-543-7500 MAIL ADDRESS: STREET 1: 1020 E. MEADOW CIRCLE CITY: PALO ALTO STATE: CA ZIP: 94303 FORMER COMPANY: FORMER CONFORMED NAME: Anacor Pharmaceuticals Inc DATE OF NAME CHANGE: 20070830 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bell Graeme CENTRAL INDEX KEY: 0001643757 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34973 FILM NUMBER: 161730779 MAIL ADDRESS: STREET 1: 1324 WAVERLY ROAD CITY: GLADWYNE STATE: PA ZIP: 19035 4 1 dp66701_4-bell.xml FORM 4 X0306 4 2016-06-24 1 0001411158 Anacor Pharmaceuticals, Inc. ANAC 0001643757 Bell Graeme C/O ANACOR PHARMACEUTICALS, INC. 1020 EAST MEADOW CIRCLE PALO ALTO CA 94303 0 1 0 0 Executive VP and CFO Common Stock 2016-06-24 4 D 0 10488 99.25 D 0 D Performance Restricted Stock Units 2016-06-24 4 D 0 8008 D Common Stock 8008 0 D Performance Restricted Stock Units 2016-06-24 4 D 0 4004 D Common Stock 4004 0 D Performance Restricted Stock Units 2016-06-24 4 D 0 5000 D Common Stock 5000 0 D Stock Option (right to buy) 69.34 2016-06-24 4 D 0 28793 D Common Stock 28793 0 D Stock Option (right to buy) 78.91 2016-06-24 4 D 0 25299 D Common Stock 25299 0 D As of the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 14, 2016 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Quattro Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, pursuant to the terms of the Merger Agreement, (i) each share of the Issuer's Common Stock held by the reporting person was disposed of in exchange for the merger consideration of $99.25 per share, (ii) each award of restricted stock units (including performance restricted stock units) and stock options became fully vested and (iii) each award of restricted stock units (including performance restricted stock units) and stock options was cancelled in exchange for the right to receive a cash payment per share in an amount equal to $99.25 less, in the case of stock options, the applicable exercise price. Includes shares acquired pursuant to the Issuer's ESPP since the reporting person's last Form 4. /s/ Lucy O. Day, Attorney-in-fact 2016-06-24